{"title":"Study suggests benefit of continuing antipsychotic during pregnancy","authors":"","doi":"10.1002/pu.31303","DOIUrl":"https://doi.org/10.1002/pu.31303","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 5","pages":"6-8"},"PeriodicalIF":0.0,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143717357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Intravenous hydroxyzine shows promise for treatment of delirium","authors":"","doi":"10.1002/pu.31305","DOIUrl":"https://doi.org/10.1002/pu.31305","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 5","pages":"8"},"PeriodicalIF":0.0,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143717351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Study finds low correspondence between known genetic variations and treatment targets","authors":"","doi":"10.1002/pu.31304","DOIUrl":"https://doi.org/10.1002/pu.31304","url":null,"abstract":"","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 5","pages":"8"},"PeriodicalIF":0.0,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143717358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Psilocybin-assisted therapy leads to personality shifts in patients with alcohol use disorder","authors":"","doi":"10.1002/pu.31300","DOIUrl":"https://doi.org/10.1002/pu.31300","url":null,"abstract":"<p>Adults with alcohol use disorder who received two sessions of psilocybin-assisted therapy demonstrated personality shifts toward normalization of abnormal trait expression, a secondary analysis of a randomized trial has found. A decrease in impulsiveness was found to be associated with reduced drinking post-treatment, with the strongest effect for psilocybin-treated individuals who had engaged in moderate- or high-risk drinking before treatment.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 5","pages":"3-4"},"PeriodicalIF":0.0,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143717354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Comprehensive study of GLP-1 effects suggests neuropsychiatric benefits","authors":"","doi":"10.1002/pu.31301","DOIUrl":"https://doi.org/10.1002/pu.31301","url":null,"abstract":"<p>A study evaluating the effects of glucagon-like peptide-1 (GLP-1) receptor agonists on 175 health outcomes found an association with lower risk of substance use, psychotic, and neurocognitive disorders in patients diagnosed with diabetes. Conversely, use of GLP-1 drugs was associated with higher risk of gastrointestinal disorders.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 5","pages":"4-5"},"PeriodicalIF":0.0,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143717355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Cohort study suggests benefit of earlier initiation of clozapine","authors":"","doi":"10.1002/pu.31297","DOIUrl":"https://doi.org/10.1002/pu.31297","url":null,"abstract":"<p>A population-based cohort study has found that among patients with first-episode schizophrenia who experienced a relapse, continuation of the same treatment or switching to a non-clozapine antipsychotic was not as effective as switching to clozapine in preventing a second relapse. The results call into question the recommendation in treatment guidelines to use clozapine only as third-line treatment. Study results were published in the February 2025 issue of <i>Lancet Psychiatry</i>.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 5","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143717349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Despite adverse event risk, anti psychotic polypharmacy has continued to rise","authors":"","doi":"10.1002/pu.31298","DOIUrl":"https://doi.org/10.1002/pu.31298","url":null,"abstract":"<p>Concurrent use of two or more antipsychotics has continued to increase over the past 50 years despite its association with a higher risk of adverse events, a systematic review and meta-analysis has found. In comparison with antipsychotic monotherapy, polypharmacy was associated with higher risk of adverse outcomes such as relapse and psychiatric hospitalization. Results of the review and meta-analysis were published online Nov. 12, 2024, in <i>Lancet Psychiatry</i>.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 5","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143717352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Psychotropic-induced weight gain and telomere length","authors":"Y. W. Francis Lam Pharm.D., FCCP","doi":"10.1002/pu.31299","DOIUrl":"https://doi.org/10.1002/pu.31299","url":null,"abstract":"<p>Research suggests that shortening of telomeres, protective cap-like structures at the ends of chromosomes, as well as inflammation, are associated with decreased cellular lifespan, and as such have been implicated in several age-related medical conditions (Gavia-García et al., 2021). A meta-analysis has reported an association between shorter telomere length and several psychiatric conditions, including anxiety, bipolar disorder, depression, post-traumatic stress disorder, and psychosis (Darrow et al., 2016).</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 5","pages":"2-3"},"PeriodicalIF":0.0,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143717353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The frustrating disconnect between genetics and psychopharmacology","authors":"Lawrence H. Price M.D.","doi":"10.1002/pu.31302","DOIUrl":"https://doi.org/10.1002/pu.31302","url":null,"abstract":"<p>Numerous criteria are utilized in selecting articles for coverage in the <i>Update</i>, and those criteria have evolved over time along with the field of psychopharmacology itself. For example, we've been covering an increasing number of papers comparing pharmacotherapy with neuromodulation over the past few years, as more high-quality studies have begun to address that issue. In contrast, our overall coverage of papers examining pharmacokinetics has declined compared with the early years of the <i>Update</i> (although we continue to highlight that topic in our monthly Drug-Drug Interactions column), as the larger field has tended to move on from this issue.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 5","pages":"7-8"},"PeriodicalIF":0.0,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143717356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
